Abstract
To accelerate progress in ending the global tuberculosis epidemic, the first UN High-Level Meeting on tuberculosis, held in 2018, resolved to close the case detection gap by 2022. However, diagnosing an additional 4 million cases of tuberculosis annually, on top of what is currently being detected, requires the immediate and expanded scale-up of systematic tuberculosis screening, followed by confirmatory testing for all individuals who screen positive. Although new confirmatory tests that are substantially more sensitive than smear microscopy are available (eg, Xpert and Xpert Ultra MTB/RIF), annual reductions in tuberculosis incidence (1·5% per year) are still far from the 4–5% annual decline needed to meet global tuberculosis elimination targets. To realise the full potential of sensitive confirmatory tests in achieving these ambitious goals, attention must now be focused on the step in the tuberculosis diagnostic cascade that misses the most patients with tuberculosis; namely, the continued reliance on symptoms to select patients for confirmatory testing.
Accepted Version (Free)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.